Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Arecor Limited has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners and 6 distinct art units, showing that prosecution is spread across multiple examination assignments rather than one centralized channel.
D' AMBROSIO, THEA is the busiest examiner, with 2 pending matters. The remaining matters are not concentrated with that examiner, so counsel should coordinate a portfolio-wide claim strategy while adapting responses to separate art-unit practices. Tracking deadlines, recurring objections, and consistency among biotechnology disclosures will be important as the record develops.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| D' AMBROSIO, THEA | 2 | 55.5% | +56.2% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866851 | COMPOSITIONS COMPRISING VANCOMYCIN | WAX, ROBERT A | — |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | KIM, YUNSOO | — |
| 18546578 | AQUEOUS COMPOSITION OF AN ENGINEERED PROTEIN CONSTRUCT COMPRISING AN FC DOMAIN | CHANDRA, GYAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17416845 | NOVEL COMPOSITION | D' AMBROSIO, THEA | 98d overdue |
| 17916504 | NOVEL FORMUATIONS | RODRIGUEZ, RAYNA B | 50d overdue |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | KIM, YUNSOO | — |
| 18546578 | AQUEOUS COMPOSITION OF AN ENGINEERED PROTEIN CONSTRUCT COMPRISING AN FC DOMAIN | CHANDRA, GYAN | — |
| 17044706 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | D' AMBROSIO, THEA | — |
| 16610826 | STABLE INSULIN FORMULATIONS | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1615 | 1 |
| 1641 | 1 |
| 1674 | 1 |
| 1628 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866851 | COMPOSITIONS COMPRISING VANCOMYCIN | WAX, ROBERT A | 1615 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | KIM, YUNSOO | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18546578 | AQUEOUS COMPOSITION OF AN ENGINEERED PROTEIN CONSTRUCT COMPRISING AN FC DOMAIN | CHANDRA, GYAN | 1674 | §102§112Other | Non-Final OA | — | Pending | Aug 15, 2023 |
| 17916504 | NOVEL FORMUATIONS | RODRIGUEZ, RAYNA B | 1628 | §102§112DP | Final Rejection | 50d overdue | Pending | Sep 30, 2022 |
| 17416845 | NOVEL COMPOSITION | D' AMBROSIO, THEA | 1654 | §103DP | Final Rejection | 98d overdue | Pending | Jun 21, 2021 |
| 17044706 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | D' AMBROSIO, THEA | 1654 | §103§112DP | Non-Final OA | — | Pending | Oct 01, 2020 |
| 16610826 | STABLE INSULIN FORMULATIONS | COFFA, SERGIO | 1658 | §103Other | Final Rejection | — | Pending | Nov 04, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArecor Limited has 7 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Thea D' Ambrosio has the most, with 2 of Arecor Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
